洛拉替尼片致中枢神经系统毒性1例分析

doi:10.19803/j.1672-8629.20230330

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (12): 1432-1434.
DOI: 10.19803/j.1672-8629.20230330

洛拉替尼片致中枢神经系统毒性1例分析

姜坤¹, 谭飞龙², 王重娟², 谭宏程¹, 游丽娜^2*

¹安宁市第一人民医院药学部，云南昆明 650302;
²昆明市延安医院药学部，云南昆明 650051

收稿日期:2023-05-26 出版日期:2023-12-15 发布日期:2023-12-15
通讯作者: ^*游丽娜,女,主管药师,临床药学。E-mail：youlinakm@126.com
作者简介:姜坤,男,主管药师,医院药学与临床药学。
基金资助:
云南省昆明市卫生科技人才培养项目（2023-SW,84）

One case of central nervous system toxicity induced by loratinib tablets

JIANG Kun¹, TANFeilong², WANG Zhongjuan², TAN Hongcheng¹, YOU Li’na^2,*

¹Department of Pharmacy, Anning First People’s Hospital, Kunming Yunnan 650302, China;
²Department of Pharmacy, Yan’an Hospital of Kunming, Kunming Yunnan 650051, China

Received:2023-05-26 Online:2023-12-15 Published:2023-12-15

摘要/Abstract

摘要： 目的探讨洛拉替尼片致中枢神经系统毒性的临床特征及处理措施。方法通过对1例间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）阳性的IV期肺腺癌患者应用洛拉替尼片致中枢神经系统毒性病例分析,结合相关文献,总结本类中枢神经系统毒性临床表现及适宜治疗方式。结果本例患者主要临床表现为对答不切题、睡眠差、情绪激动、易怒、不识人,与国内外报道的洛拉替尼相关性中枢神经毒性相似,立即采取停药措施,给予奥氮平对症处理,3 d后完全缓解,1周后降低洛拉替尼片剂量重启治疗,未再出现中枢神经系统症状。结论洛拉替尼片相关中枢神经系统毒性可严重影响患者生存质量,应引起重视。

关键词: 洛拉替尼片, 药品不良反应, 中枢神经系统毒性, 间变性淋巴瘤激酶, 肺腺癌

Abstract: Objective To explore the clinical characteristics and disposal of central nervous system toxicity caused by loratinib tablets. Methods One case of central nervous system toxicity caused by loratinib tablets in a stage IV lung adenocarcinoma patient with anaplastic lymphoma kinase (ALK) positivity was analyzed. By retrieving related literature, the clinical manifestations and appropriate treatments of such central nervous system toxicity were summarized. Results The main clinical manifestations were off-the-point answers, poor sleep, emotional excitement, irritability and inability to recognize others. This medication was discontinued immediately and symptomatic treatment with olanzapine was provided. The symptoms disappeared after three days, and the patient resumed the treatment with loratinib tablets after a week at a smaller dose. Conclusion Clinicians should be alert to the central nervous system toxicity associated with loratinib tablets, which can impact the quality of life of patients.

Key words: lorlatinib tablets, adverse drug reaction, central nervous system toxicity, anaplastic lymphoma kinase, lung adenocarcinoma

中图分类号:

姜坤, 谭飞龙, 王重娟, 谭宏程, 游丽娜. 洛拉替尼片致中枢神经系统毒性1例分析[J]. 中国药物警戒, 2023, 20(12): 1432-1434.

JIANG Kun, TANFeilong, WANG Zhongjuan, TAN Hongcheng, YOU Li’na. One case of central nervous system toxicity induced by loratinib tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1432-1434.

参考文献

[1] CHEN W, JIN D, SHI Y, et al.The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain[J]. Cancer Med, 2020, 9(12): 4350-4359.
[2] CHEN BC.New drugs for the treatment of non-small cell lung cancer-lorlatinib[J]. Herald of Medicine(医药导报), 2019, 38(7): 975-983.
[3] CHEN YC, HAN H, WEI JP, et al.Research progress in the efficacy and safety of alk inhibitors in the treatment of NSCLC brain metastasis[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2023, 26(5): 400-406.
[4] Organization of the Guidelines Working Committee of the Chinese Clinical Oncology Society. Guidelines for the diagnosis and treatment of non-small cell lung cancer(中国临床肿瘤学会非小细胞肺癌诊疗指南)[M]. Beijing: People’s Health Press, 2022.
[5] BETTON M, GOUNANT V, SANNIER A, et al.Minimal change disease induced by lorlatinib[J]. J Thorac Oncol, 2018, 13(8): e154-e156.
[6] HAKAMATA J, NAKADA H, MURAMATSU H, et al. Lorlatinib-induced visual and auditory hallucinations: a case report[J]. Clin Case Rep, 2021, 9(8): 10.1002/ccr3.4040.
[7] ZHU VW, NAGASAKA M, KUBOTA T, et al.Symptomatic CNS radiation necrosis requiring neurosurgical resection during treatment with lorlatinib in ALK-rearranged NSCLC: a report of two cases[J]. Lung Cancer (Auckl), 2020, 11: 13-18.
[8] LAN ZY.A case of mental disorder caused by loratinib[J]. Journal of International Psychiatry(国际精神病学杂志), 2021, 48(3): 575-576.
[9] SISI M, FUSAROLI M, DE GIGLIO A, et al.Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event reporting system[J]. Target Oncol, 2022, 17(1): 43-51.
[10] DAGOGO-JACK I, ABBATTISTA A, MURPHY JF, et al.Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies[J]. J Thorac Oncol, 2023, 18(1): 67-78.
[11] ZHENG DN, ZHOU HF, REN CY, et al.ADR signal mining and analysis of adverse drug reaction of ceritinib[J]. China Pharmacy(中国药房), 2021, 32(2): 236-240.
[12] Pfizer Inc.OR BR ENA®(lorlatinib) tablets, for oral use. Initial U.S. Reference ID: 4756573[EB/OL]. [2023-03-26]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf.
[13] Novartis Pharma Stein AG.(ceritinib) tablets, for oral use[EB/OL].[2022-06-26]. https://zy.yaozh.com/instruct/sms20210831/89.pdf.
[14] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[15] ZHOU Q, LU S, LI Y, et al.Chinese expert consensus on management of special adverse effects associated with lorlatinib[J]. Chinese Journal of Lung Cancer(中国肺癌杂志) , 2022, 25(8): 555-566.
[16] BAUER TM, FELIP E, SOLOMON BJ, et al.Clinical management of adverse events associated with lorlatinib[J]. Oncologist, 2019, 24(8): 1103-1110.
[17] U.S.Department of Health and Human Services. National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[EB/OL]. [2023-04-02]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.

洛拉替尼片致中枢神经系统毒性1例分析

One case of central nervous system toxicity induced by loratinib tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.